Antihemophilic factor (recombinant), full length - Biologic Drug Details

Summary for antihemophilic factor (recombinant), full length

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for antihemophilic factor (recombinant), full length Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for antihemophilic factor (recombinant), full length Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	5,804,420	2017-04-18	DrugPatentWatch analysis and company disclosures
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,248,363	2019-11-23	DrugPatentWatch analysis and company disclosures
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,309,663	2019-08-17	DrugPatentWatch analysis and company disclosures
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,720,001	2019-10-18	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for antihemophilic factor (recombinant), full length Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,248,363	2019-11-23	Patent claims search
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,309,663	2019-08-17	Patent claims search
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	6,720,001	2019-10-18	Patent claims search
Bayer Healthcare Llc	KOVALTRY	antihemophilic factor (recombinant), full length	For Injection	125574	9,700,486	2034-04-23	Patent claims search

Market Dynamics and Financial Trajectory for Antihemophilic Factor (Recombinant)

Last updated: February 23, 2026

What Is the Current Market Size and Growth Outlook?

The global recombinant antihemophilic factor (rAHF) market was valued at approximately $11.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030, reaching roughly $21 billion by 2030.

Factors: Rising prevalence of hemophilia, advancements in recombinant technology, and increased awareness about gene therapy contribute to growth. The World Federation of Hemophilia estimates 400,000 individuals worldwide with hemophilia A or B. Europe and North America account for over 70% of the market, driven by higher diagnosis rates and established healthcare infrastructure.

What Are the Key Drivers and Barriers?

Drivers:

• Increasing diagnosis rates: Improved screening, better awareness, and access to healthcare expand the treated population.
• Treatment innovations: Extended half-life (EHL) products reduced infusion frequency, improving adherence.
• Emerging therapies: Gene therapies and novel therapeutics challenge traditional recombinant products but also expand market opportunities for combination treatments.

Barriers:

• High product costs: Annual treatment costs can exceed $250,000 per patient.
• Development hurdles: Complex manufacturing of recombinant proteins increases R&D costs.
• Competition from non-recombinant therapies: Plasma-derived factors and emerging gene therapies impact sales.

How Do Market Participants Compare?

Major pharmaceutical companies include:

• Pfizer (XynthoSet, ReFacto): Leading with robust R&D pipeline.
• Bayer (Kogenate FS): Known for early adoption of recombinant technology.
• Sanofi (Afstyla)): Focused on extended half-life formulations.
• CSL Behring (Helixate FS)): Focuses on plasma-derived and recombinant products.

Innovative firms investing heavily in gene therapy include BioMarin and Spark Therapeutics, poised to disrupt traditional recombinant markets.

What Is the Financial Trajectory of Key Drugs?

Drug Name	Year Approved	Company	Type	Price per Year	Market Share (2022)	Development Stage
ReFacto (Bayer)	1990	Bayer	Recombinant standard	$250,000	20%	Established, patent expiration in 2024
Xyntha (Pfizer)	2009	Pfizer	Extended half-life (EHL)	$300,000	25%	Market leader, new formulations in pipeline
Afstyla (Sanofi)	2015	Sanofi	EHL recombinant	$310,000	10%	Competing for market share
Elocta (Elocta)	2014	AbbVie	EHL formulation	$290,000	15%	Growing with newer indications

Revenue Trends:

• Pfizer's Xyntha leads with over $2.5 billion in 2022 sales.
• Revenues are consolidating as EHL products gain market share.
• Price erosion is occurring, particularly among biosimilar entries post-patent expiration.

Investment in R&D:

• Global biologics R&D expenditure on hemophilia exceeds $1.2 billion annually.
• Most companies are investing 15-20% of revenues into new formulations, gene therapy integrations, or delivery methods.

How Do Pricing and Reimbursement Strategies Affect Market Dynamics?

Pricing strategies are driven by payers' negotiations and reimbursement policies. Governments in Europe and the US account for approximately 60% of sales, with value-based pricing models increasingly common. Manufacturers offer patient assistance programs and tiered pricing to gain market access.

Reimbursement challenges can lead to access delays and limit uptake, especially in emerging markets. Biosimilar competition pressures prices downward, affecting profitability margins.

What Is the Future Outlook?

The future of recombinant antihemophilic factor includes:

• Growth driven mainly by extended half-life products and emerging gene therapies.
• A potential plateau or decline in traditional recombinant product sales post-2025 as gene therapies become affordable and widely adopted.
• Mergers and collaborations aimed at balancing innovation with cost management.

Why Are Recent Patent Expirations Significant?

Patents for first-generation recombinant products, like ReFacto in 2024, will enable biosimilar entry, increasing price competition and eroding margins for incumbent firms. Biosimilars are expected to capture 25-35% of the market within five years of launch, leading to significant pricing declines.

What Are the Key Policies Impacting Market Growth?

• US Medicare and Medicaid policies on drug pricing influence access.
• European Union's ‘basic health policy’ emphasizes cost-effective therapies.
• International bodies advocate for drug affordability, pressuring prices globally.
• Investment incentives for gene therapy development are increasing, with regulatory pathways in the US and EU becoming more streamlined.

Summary of Regulatory Landscape

Regulatory Agency	Approval Process	Current Focus	Notable Updates
FDA (US)	BLA (Biologics License)	Biosimilars, gene therapies	Fast Track & RMAT pathways
EMA (EU)	Marketing Authorization	Gene therapy, biosimilar pathways	Adaptive pathways for advanced therapies

Key Takeaways

• The recombinant antihemophilic factor market exceeds $11.5 billion in 2022, expected to hit $21 billion by 2030.
• Growth Drivers: Rising diagnoses, innovation in EHL products, and gene therapy approaches.
• Major challenges include high costs, patent expirations, biosimilar competition, and regulatory hurdles.
• Leading companies have substantial sales, with Pfizer's Xyntha and Sanofi's Afstyla dominating.
• Patent expirations in 2024 will catalyze biosimilar entries, pushing prices downward.
• Market focus shifts toward gene therapies, which threaten traditional recombinant product revenues.
• Policy and reimbursement structures significantly influence pricing and market accessibility.

FAQs

1. What are the main differentiators among recombinant antihemophilic products?
   Extended half-life formulations provide less frequent infusions, improving compliance. Manufacturing processes impact purity and immunogenicity, influencing safety profiles.

2. How will biosimilars impact the recombinant market?
   Biosimilars will lower prices, increase competition, and potentially reduce revenue for original biologics by up to 35% over five years post-patent expiry.

3. What role do gene therapies play in market evolution?
   Gene therapies can offer a one-time curative approach, threatening long-term sales of recombinant products, especially in developed markets.

4. Are emerging markets ready for recombinant products?
   Limited infrastructure, high costs, and regulatory challenges restrict access in low-income regions; growth is expected but at a slower pace than in developed nations.

5. What are the regulatory hurdles for new recombinant therapies?
   Regulatory bodies require extensive efficacy and safety data, particularly for biosimilar substitution, with evolving pathways that expedite approval for innovative treatments.

---

References

1. World Federation of Hemophilia. (2022). Global Hemophilia Market Report.
2. MarketWatch. (2023). Recombinant Hemophilia Drugs Market Size, Trends & Forecasts.
3. FDA. (2022). Guidance for Industry: Biosimilar Biological Products.
4. EMA. (2022). Guidance on the Regulatory Framework for Gene Therapy.
5. IQVIA. (2022). Global Hemophilia Pipeline and Market Analysis.